What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction

What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction

The PARAGON-HF clinical trial suggested that sacubitril/valsartan may become a treatment option for particular subgroups of patients with heart failure and preserved ejection fraction (HFpEF). However, the proportion of real-world HFpEF patients who are theoretically superimposable with the PARAGON-...

Full description

Bibliographic Details
Main Authors: René Rettl, Theresa-Marie Dachs, Franz Duca, Christina Binder, Fabian Dusik, Benjamin Seirer, Johannes Schönauer, Christina Kronberger, Luciana Camuz Ligios, Christian Hengstenberg, Nina Derkits, Johannes Kastner, Roza Badr Eslam, Diana Bonderman
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Journal of Clinical Medicine
Subjects:
heart failure with preserved ejection fraction
HFpEF
PARAGON-HF
real-world
outcomes
Online Access:https://www.mdpi.com/2077-0383/9/11/3669

Internet

https://www.mdpi.com/2077-0383/9/11/3669

Similar Items